2-Anilino-4-(thiazol-5-yl)pyrimidine CDK Inhibitors: Synthesis, SAR Analysis, X-ray Crystallography, and Biological Activity

Journal of Medicinal Chemistry

Volumn 47, Issue 7, 2004, Pages 1662-1675

  Wang, Shudong ^a   Meades, Christopher ^a   Wood, Gavin ^a   Osnowski, Andrew ^a   Anderson, Sian ^a   Yuill, Rhoda ^a   Thomas, Mark ^a   Mezna, Mokdad ^a   Jackson, Wayne ^a   Midgley, Carol ^a   Griffiths, Gary ^a   Fleming, Ian ^a   Green, Simon ^a   McNae, Iain ^b   Wu, Su Ying ^b   McInnes, Campbell ^a   Zheleva, Daniella ^a   Walkinshaw, Malcolm D ^b   Fischer, Peter M ^a  

^a CYCLACEL LTD   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 ANILINO 4 (THIAZOL 5 YL)PYRIMIDINE; 4 (2,4 DIMETHYLTHIAZOL 5 YL)PYRIMIDIN 2 YLAMINE; [4 (2 AMINO 4 METHYLTHIAZOL 5 YL)PYRIMIDIN 2 YL](3 NITROPHENYL)AMINE; ADENOSINE TRIPHOSPHATE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; CDC2-CDC28 KINASES; CELL CYCLE; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 9; HUMANS; MOLECULAR STRUCTURE; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 12144286803     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0309957     Document Type: Article

References (43)

1. Malumbres, M.; Barbacid, M. To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer 2001, 1, 222-231.
2. Kitagawa, M.; Higashi, H.; Suzuki-Takahashi, I.; Segawa, K.; Hanks, S. K.; et al. Phosphorylation of E2F-1 by cyclin A-cdk2. Oncogene 1995, 10, 229-236.
3. Krek, W.; Xu, G.; Livingston, D. M. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. Cell 1995, 83, 1149-1158.
4. Chen, Y.-N. P.; Sharma, S. K.; Ramsey, T. M.; Jiang, L.; Martin, M. S.; et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 4325-4329.
5. Napolitano, G.; Majello, B.; Lania, L. Role of cyclinT/Cdk9 complex in basal and regulated transcription (Review). Int. J. Oncol. 2002, 21, 171-177.
6. Fischer, P. M.; Endicott, J.; Meijer, L. Cyclin-dependent kinase inhibitors. Progress in Cell Cycle Research; Editions de la Station Biologique de Roscoff: Roscoff, France, 2003; pp 235-248.
7. Hardcastle, I. R.; Golding, B. T.; Griffin, R. J. Designing inhibitors of cyclin-dependent kinases. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 325-348.
8. Toogood, P. L. Cyclin-dependent kinase inhibitors for treating cancer. Med. Res. Rev. 2001, 21, 487-498.
9. Fischer, P. M.; Gianella-Borradori, A. CDK inhibitors in clinical development for the treatment of cancer. Exp. Opin. Invest. Drugs 2003, 12, 955-970.
10. Sausville, E. A. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol. Med. 2002, 8, S32-S37.
11. van den Heuvel, S.; Harlow, E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 1993, 262, 2050-2054.
12. Hu, B.; Mitra, J.; Van den Heuvel, S.; Enders, G. H. S and G2 phase roles for Cdk2 revealed by inducible expression of a dominant-negative mutant in human cells. Mol. Cell. Biol. 2001, 21, 2755-2766.
13. Tetsu, O.; McCormick, F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003, 3, 233-245.
14. Ortega, S.; Prieto, I.; Odajima, J.; Martin, A.; Dubus, P.; et al. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat. Genet. 2003, 35, 25-31.
15. Berthet, C.; Aleem, E.; Coppola, V.; Tessarollo, L.; Kaldis, P. Cdk2 knockout mice are viable. Curr. Biol. 2003, 13, 1775-1785.
16. McClue, S. J.; Blake, D.; Clarke, R.; Cowan, A.; Cummings, L.; et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int. J. Cancer 2002, 102, 463-468.
17. Lees, J. A.; Weinberg, R. A. Tossing monkey wrenches into the clock: new ways oftreating cancer. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 4421-4223.
18. Wu, S. Y.; McNae, I.; Kontopidis, G.; McClue, S. J.; McInnes, C.; et al. Discovery of a Novel Family of CDK Inhibitors with the Program LIDAEUS: Structural Basis for Ligand-Induced Disordering of the Activation Loop. Structure 2003, 11, 399-410.
19. Bredereck, H.; Effenberger, F.; Botsch, H. Acid amide reactions. XLV. Reactivity of formamidines, dimethylformamide diethyl acetal (amide acetal), and bis(dimethylamino)methoxymethane (aminal ester). Chem. Ber. 1964, 97, 3397-3406.
20. Zimmermann, J.; Caravatti, G.; Mett, H.; Meyer, T.; Müller, M.; et al. Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC). Arch. Pharm. Pharm. Med. Chem. 1996, 329, 371-376.
21. Schulze-Gahmen, U.; De Bondt, H. L.; Kim, S. H. High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design. J. Med. Chem. 1996, 39, 4540-4546.
22. Russo, A. A.; Jeffrey, P. D.; Pavletich, N. P. Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat. Struct. Biol. 1996, 3, 696-700.
23. Knockaert, M.; Greengard, P.; Meijer, L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 2002, 23, 417-425.
24. Zarkowska, T.; Mittnacht, S. Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J. Biol. Chem. 1997, 272, 12738-12746.
25. Oelgeschlager, T. Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control. J. Cell. Physiol. 2002, 190, 160-169.
26. Hughes, T. A.; Cook, P. R. Mimosine arrests the cell cycle after cells enter S-phase. Exp. Cell Res. 1996, 222, 275-280.
27. Jackson, P. K.; Chevalier, S.; Philippe, M.; Kirschner, M. W. Early events in DNA replication require cyclin E and are blocked by p21CIP1. J. Cell. Biol. 1995, 130, 755-769.
28. Ohtsubo, M.; Theodoras, A. M.; Schumacher, J.; Roberts, J. M.; Pagano, M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol. Cell. Biol. 1995, 15, 2612-2624.
29. Strausfeld, U. P.; Howell, M.; Descombes, P.; Chevalier, S.; Rempel, R. E. et al. Both cyclin A and cyclin E have S-phase promoting (SPF) activity in Xenopus egg extracts. J. Cell Sci. 1996, 109, 1555-1563.
30. Coverley, D.; Laman, H.; Laskey Ronald, A. Distinct roles for cyclins E and A during DNA replication complex assembly and activation. Nat. Cell Biol. 2002, 4, 523-528.
31. Pagano, M.; Pepperkok, R.; Verde, F.; Ansorge, W.; Draetta, G. Cyclin A is required at two points in the human cell cycle. EMBO J. 1992, 11, 961-971.
32. Lukas, C.; Sorensen, C. S.; Kramer, E.; Santoni-Ruglu, E.; Lindeneg, C.; et al. Accumulation of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex. Nature 1999, 401, 815-818.
33. Ljungman, M.; Paulsen, M. T. The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382. Mol. Pharmacol. 2001, 60, 785-789.
34. Chao, S.-H.; Price, D. H. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J. Biol. Chem. 2001, 276, 31793-31799.
35. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276, 307-326.
36. Leslie, A. G. W. Recent changes to the MOSFLM package for processing film and image plate data. Joint CCP4 + ESF-EAMCB Newsletter on Protein Crystallography; 1992, No. 26. http://www.ccp4.ac.uk/main.html.
37. Vagin, A.; Teplyakov, A. MOLREP: an automated program for molecular replacement. J. Appl. Crystallogr. 1997, 30, 1022-1025.
38. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. 1997, D53, 240-255.
39. Sheldrick, G. M.; Schneider, T. R. SHELXL: high-resolution refinement. Methods Enzymol. 1997, 277, 319-343.
40. Brunger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; et al. Crystallography & NMR System: a new software suite for macromolecular structure determination. Acta Crystallogr. 1998, D54, 905-921.
41. Jones, T. A.; Zou, J. Y.; Cowan, S. W.; Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr., Sect. A: Found. Crystallogr. 1991, A47, 110-119.
42. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
43. Haselsberger, K.; Peterson, D. C.; Thomas, D. G.; Darling, J. L. Assay of anticancer drugs in tissue culture: comparison of a tetrazolium-based assay and a protein binding dye assay in short-term cultures derived from human malignant glioma. Anti Cancer Drugs 1996, 7, 331-338.